RAPS is closely monitoring developments in the Coronavirus (COVID-19) outbreak. See our public safety page for the latest updates.

Regulatory Focus™ > News Articles > Regulatory Update

Regulatory Update

Posted 01 December 2010 | By

The US Food and Drug Administration (FDA) held a two-day part 15 public hearing on 2-3 November to discuss with stakeholders an abbreviated approval pathway for biosimilars and interchangeable biological products. The hearing was in response to the Biologics Price Competition and Innovation Act of 2009 (BPCI). The hearing provided input about biosimilars from public health organizations, academia and all parts of the biopharmaceutical industry.

Regulatory Focus newsletters

All the biggest regulatory news and happenings.


Regulatory Focus™ is doing essential, non-biased journalism during this unprecedented time. We appreciate your support as we bring you the news and intelligence you need to make an impact on global healthcare.

Regulatory Focus™ provides the intelligence you need to impact global healthcare during this crisis. Thank you for your support.